Pharming Group N.V.
PHAR
$11.72
-$0.63-5.10%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 06/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | 339.84M | 339.84M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | 339.84M | 339.84M |
| Cost of Revenue | -- | -- | -- | 36.33M | 36.33M |
| Gross Profit | -- | -- | -- | 303.51M | 303.51M |
| SG&A Expenses | -- | -- | -- | 199.15M | 204.85M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -3.15M | -3.15M |
| Total Operating Expenses | -- | -- | -- | 320.19M | 327.99M |
| Operating Income | -- | -- | -- | 19.64M | 11.84M |
| Income Before Tax | -- | -- | -- | 3.48M | 3.48M |
| Income Tax Expenses | -- | -- | -- | 12.00M | 12.00M |
| Earnings from Continuing Operations | -- | -- | -- | -8.51 | -8.51 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | 313.00K | 313.00K |
| Net Income | -- | -- | -- | -8.20M | -8.20M |
| EBIT | -- | -- | -- | 19.64M | 11.84M |
| EBITDA | -- | -- | -- | 35.62M | 27.82M |
| EPS Basic | -- | -- | -- | -0.01 | -0.01 |
| Normalized Basic EPS | -- | -- | -- | 0.01 | 0.00 |
| EPS Diluted | -- | -- | -- | -0.01 | -0.01 |
| Normalized Diluted EPS | -- | -- | -- | 0.01 | 0.00 |
| Average Basic Shares Outstanding | -- | -- | -- | 2.61B | 2.61B |
| Average Diluted Shares Outstanding | -- | -- | -- | 2.61B | 2.61B |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |